双长效支气管扩张剂在慢性阻塞性肺疾病治疗中的研究进展  

Research progress of double long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease

作　　者：李倩[1] 毛山[1] LI Qian;MAO Shan(Department of Respiratory,Nanjing Hospital Affiliated to Nanjing Medical University,Nanjing 210006,Jiangsu Province,China)

机构地区：[1]南京医科大学附属南京医院,南京市第一医院呼吸科,江苏南京210006

出　　处：《世界临床药物》2020年第2期149-154,共6页World Clinical Drug

基　　金：南京市科技发展计划项目(201803007);南京市医学科技发展项目(YKK17119)。

摘　　要：长效支气管扩张剂是稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)治疗的基石。固定剂量长效β2受体激动剂(long actingβ2 agonist,LABA)/长效抗胆碱能药物(long acting muscarinic antagonist,LAMA)复方制剂被慢性阻塞性肺疾病全球倡议推荐用于COPD的治疗。为了更深入了解已经上市的多种LABA/LAMA复方制剂如维兰特罗/乌美溴铵、茚达特罗/格隆溴铵、福莫特罗/格隆溴铵及奥达特罗/噻拖溴铵等的疗效和安全性,本文对LABA/LAMA一些重要临床研究作一综述,旨在为COPD患者提供个体化的治疗方案。Long-acting bronchodilation is the cornerstone for the treatment of chronic obstructive pulmonary disease(COPD).Fixed dose combinations of long actingβ2 agonist(LABA)/long acting muscarinic antagonist(LAMA)were recommended for the treatment of symptomatic COPD patients by global guidelines.This review comprehensively described the clinical efficacy and safety of four approved LABA/LAMA fixed-dose combinations:vilanterol/umeclidinium,indacaterol/glycopyrronium,formoterol/aclidinium,and olodaterol/tiotropium,in order to provide a better understanding of the benefits of these therapies and to inform healthcare providers and patients on their appropriate uses.

关 键 词：慢性阻塞性肺疾病 固定剂量组合制剂 长效Β2受体激动剂 长效抗胆碱能药物 

分 类 号：R563[医药卫生—呼吸系统]